Partner Headlines - THRX

  1. Theravance, Inc. Appoints Michael Faerm as Chief Business Officer

    GuruFocus
  2. Insiders' New Buys : MAC, SPB, PDVW, HNSN, THRX, RSG, CVX

    GuruFocus
  3. Seth Klarman's Trades During Q1 2015

    GuruFocus
  4. Richard Perry's Fourth-Quarter Transactions Had High Impact on ...

    GuruFocus
  5. Mylan Makes Deals In Women's Health, Lung Disease

    IBD
  6. Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX

    GuruFocus
  7. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  8. Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung ...

    GuruFocus
  9. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD
  10. Barron's Recap: Ready To Wear?

    Benzinga
  11. UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds ...

    Benzinga
  12. UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends ...

    Benzinga
  13. Theravance, Inc. Appoints Theodore J. Witek, Jr. As Senior VP, ...

    Benzinga
  14. UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion

    Benzinga
  15. Benzinga's Top Downgrades

    Benzinga
  16. UPDATE: Glaxo, Theravance Report Positive Data from Two Studies ...

    Benzinga
  17. Theravance Announces Positive Results From a Phase 2 Study of ...

    Benzinga
  18. Theravance Announces Initiation of Phase 2b Study With TD-42 ...

    Benzinga
  19. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  20. Morgan Stanley Expects Theravance to Continue to Underperform ...

    Benzinga
  21. Top 2013 Drug Approvals: Pharma Stocks

    YCharts
  22. Positive data for asthma drug

    IBD
  23. Theravance, Glaxo COPD Drug Does Well In Asthma

    IBD
  24. Seth Klarman Buys Micron Technology, Theravance, PBF Energy, ...

    GuruFocus
  25. GlaxoSmithKline

    IBD
  26. US Stock Futures Signal Flat Start On Wall Street

    Benzinga
  27. Relvar Ellipta Approved in Japan for Treatment of Asthma

    Benzinga
  28. Glaxo, Theravance Confirm Positive CHMP Opinion for Relvar Ellipta

    Benzinga
  29. Glaxo, Theravance Confirms FDA Panel Has Recommended Approval ...

    Benzinga
  30. Theravance Reports Results from Phase 2B Study 0091 with TD-42 ...

    Benzinga
  31. Missed Klarman’s 47% Gainer? His Other Value Pick

    YCharts
  32. Seth Klarman's Top 5 Second Quarter Holdings

    GuruFocus
  33. Perrigo-Elan Merger Creates Unlikely Pharma Union

    IBD
  34. UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of ...

    Benzinga
  35. Theravance to Offer $250 Million Convertible Subordinated Notes ...

    Benzinga
  36. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus
  37. Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

    Benzinga
  38. Theravance Offers FDA Briefing Documents for Panel Meeting on ...

    Benzinga
  39. Theravance Enters Agreement With Alfa Wassermann Worth Up To ...

    Benzinga
  40. The Baupost Group's Favorite Stocks

    Benzinga
  41. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 24,682 ...

    GuruFocus
  42. GSK and Theravance Announce Completion of the Phase III Programme ...

    Benzinga
  43. Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX

    GuruFocus
  44. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 60, ...

    GuruFocus
  45. Theravance Inc. (THRX) CEO Rick E Winningham sells 75,749 Shares

    GuruFocus
  46. A Peek Into The Market Before The Trading Starts

    Benzinga
  47. GSK and Theravance Announce Regulatory Submissions for FF/VI ...

    Benzinga
  48. Target, Amgen Among Stocks Hitting 52-Week Highs Wednesday

    FoxBusiness
  49. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  50. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FoxBusiness
  51. Health Care Sector Wrap

    FoxBusiness
  52. Health Care Sector Wrap

    FoxBusiness
  53. GSK and Theravance Announce Positive Results From Four Pivotal ...

    Benzinga
  54. Theravance Inc. Reports Operating Results (10-K)

    GuruFocus
  55. UPDATE: Morgan Stanley Initiates Underweight, $12 PT on Theravance

    Benzinga
  56. Morgan Stanley Initiates Theravance at Underweight

    Benzinga
  57. Afternoon Movers; Markets Moved Higher

    Benzinga
  58. Morning Market Losers

    Benzinga
  59. From Earlier: GSK and Theravance Announce Initial Outcomes From ...

    Benzinga
  60. UPDATE: Piper Jaffray Raises Price Target on Theravance to $35

    Benzinga
  61. Piper Jaffray Raises PT on Theravance to $35

    Benzinga
  62. Notable Put Options Activity in Theravance

    Benzinga
  63. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 10, ...

    GuruFocus
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!